0001127602-21-007951.txt : 20210225
0001127602-21-007951.hdr.sgml : 20210225
20210225175428
ACCESSION NUMBER: 0001127602-21-007951
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210223
FILED AS OF DATE: 20210225
DATE AS OF CHANGE: 20210225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoge Stephen
CENTRAL INDEX KEY: 0001760669
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 21682245
MAIL ADDRESS:
STREET 1: C/O MODERNA, INC.
STREET 2: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-02-23
0001682852
Moderna, Inc.
MRNA
0001760669
Hoge Stephen
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
President
Common Stock
2021-02-23
4
M
0
10000
.99
A
1629597
D
Common Stock
2021-02-23
4
S
0
500
136.83
D
1629097
D
Common Stock
2021-02-23
4
S
0
300
137.97
D
1628797
D
Common Stock
2021-02-23
4
S
0
200
139.14
D
1628597
D
Common Stock
2021-02-23
4
S
0
200
140.15
D
1628397
D
Common Stock
2021-02-23
4
S
0
300
141.61
D
1628097
D
Common Stock
2021-02-23
4
S
0
1300
143.49
D
1626797
D
Common Stock
2021-02-23
4
S
0
1564
144.58
D
1625233
D
Common Stock
2021-02-23
4
S
0
1100
145.48
D
1624133
D
Common Stock
2021-02-23
4
S
0
1200
146.73
D
1622933
D
Common Stock
2021-02-23
4
S
0
1551
147.85
D
1621382
D
Common Stock
2021-02-23
4
S
0
800
148.78
D
1620582
D
Common Stock
2021-02-23
4
S
0
685
149.98
D
1619897
D
Common Stock
2021-02-23
4
S
0
5300
150.62
D
1614597
D
Common Stock
2021-02-24
4
S
0
5000
150.41
D
1609597
D
Common Stock
4116
I
By Valhalla, LLC
Common Stock
151933
I
By Trust
Stock Option (Right to Buy)
.99
2021-02-23
4
M
0
10000
0
D
2023-08-19
Common Stock
10000
597431
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.71 to $137.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.85 to $138.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.90 to $139.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.10 to $140.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.37 to $141.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.96 to $143.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.06 to $145.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.10 to $146.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.30 to $147.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.36 to $148.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.37 to $149.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.51 to $150.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.60 to $151.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
This option is fully vested and exercisable.
/s/ Brian Sandstrom, as Attorney-in-Fact
2021-02-25